AtriCure Inc
$ 39.25
8.10%
04 Dec - close price
- Market Cap 1,805,224,000 USD
- Current Price $ 39.25
- High / Low $ 39.73 / 36.38
- Stock P/E N/A
- Book Value 9.59
- EPS -0.61
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.06 %
- 52 Week High 43.11
- 52 Week Low 28.29
About
AtriCure, Inc. is a prominent medical device company headquartered in Mason, Ohio, focusing on pioneering technologies for surgical ablation in the treatment of cardiac arrhythmias, particularly atrial fibrillation. The company's innovative product portfolio is utilized across a broad spectrum of healthcare facilities in the U.S. and international markets, including Europe and Asia. Committed to advancing cardiac care, AtriCure emphasizes the integration of advanced technology and rigorous clinical research to improve patient outcomes and drive the adoption of minimally invasive surgical techniques. As a leader in its field, AtriCure is well-positioned to address the evolving needs of the cardiac care market.
Analyst Target Price
$51.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-07-25 | 2023-05-02 | 2023-02-21 |
| Reported EPS | -0.01 | -0.02 | -0.14 | -0.08 | -0.17 | -0.17 | -0.28 | -0.21 | -0.2 | -0.11 | -0.23 | -0.09 |
| Estimated EPS | -0.11 | -0.167 | -0.2234 | -0.1488 | -0.19 | -0.17 | -0.23 | -0.23 | -0.31 | -0.3 | -0.34 | -0.18 |
| Surprise | 0.1 | 0.147 | 0.0834 | 0.0688 | 0.02 | 0 | -0.05 | 0.02 | 0.11 | 0.19 | 0.11 | 0.09 |
| Surprise Percentage | 90.9091% | 88.024% | 37.3321% | 46.2366% | 10.5263% | 0% | -21.7391% | 8.6957% | 35.4839% | 63.3333% | 32.3529% | 50% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.104 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATRC
2025-10-16 17:08:02
This article provides an AI-driven analysis for Atricure Inc. (NASDAQ: ATRC), highlighting a strong near-term sentiment that influences neutral mid and long-term outlooks. It details specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The analysis also emphasizes an exceptional risk-reward short setup targeting 11.3% downside.
2025-10-11 18:28:37
Analysts have given AtriCure, Inc. (NASDAQ:ATRC) an average recommendation of "Moderate Buy." The article details recent insider transactions and institutional trading activities, highlighting significant increases in holdings by several hedge funds. It also provides a company profile for AtriCure, Inc., outlining its products and market presence.
2024-10-16 00:00:00
AtriCure, Inc. has launched the cryoSPHERE MAX™ cryoablation probe, designed to optimize Cryo Nerve Block™ therapy for post-operative pain management. This new probe significantly reduces freeze times and enhances efficiency for surgeons and patients. The cryoSPHERE MAX features a larger 10 mm ball tip, providing improved tissue coverage and greater heat extraction compared to previous models.
2024-10-15 00:00:00
AtriCure (Nasdaq: ATRC) has launched its new CryoSphere Max cryoablation probe, designed to optimize Cryo Nerve Block therapy and reduce freeze times by 50% compared to its first-generation probe. This next-generation device offers upgrades in insulation, gas utilization, tactile feedback, and real-time temperature monitoring, aiming to enhance surgical efficiency and patient outcomes. The launch follows the introduction of the CryoSphere+ cryoablation probe six months prior.
2024-10-11 00:00:00
AtriCure, Inc. has received CE Mark regulatory approval for its EnCompass Clamp in the European Union, following its successful U.S. launch in 2022. This expansion allows AtriCure to offer its heart ablation technology to European patients and surgeons, strengthening its global presence in the growing cardiac ablation market. The article also highlights advancements from other industry players like Medtronic, GE HealthCare, and Boston Scientific.
2024-08-15 13:41:00
AtriCure announced a $45 million expansion of its Mason, Ohio global headquarters, which will double its size by adding 120,000 square feet for laboratory, R&D, office, and advanced manufacturing operations. This expansion is expected to create hundreds of new high-paying jobs in the Greater Cincinnati area.
